,i  #aahth ,,congress  #ast ,session    
,h4 ,r4 #dddi  ,,in ,,the ,,house ,,of  
,,representatives  ,june #cj1 #bjbc,mr4 
,torres of ,new ,york introduced the    
following bill2 which was referred to   
the ,committee on ,energy and ,commerce 
,a ,,bill  ,to establish the ,commission
 on ,strengthening the ,domestic        
,pharmaceutical ,supply ,chain1 and for 
other purposes4  #a4 ,short title ,this 
,act may be cited as the ,pharmaceutical
 ,security ,production ,act4  #b4       
,commission on ,strengthening the       
,domestic ,pharmaceutical ,supply ,chain
  7a7 ,establishment ,there is          
established a commission to be known as 
the ,commission on ,strengthening the   
,domestic ,pharmaceutical ,supply ,chain
 7in this section referred to as the    
,commission7 to assess the current      
security and vulnerabilities of the     
,united ,states pharmaceutical supply   
chain4  7b7 ,duties ,the duties of the  
,commission are the following3 7#a7     
,determine concrete timelines and       

metrics for success for the             
,pharmaceutical ,manufacturing in       
,america program of the ,biomedical     
,advanced ,research and ,development    
,authority to produce advanced          
pharmaceutical ingredients for medicines
 included in the essential medicines    
list4  7#b7 ,evaluate and identify      
vulnerabilities in the existing ,united 
,states pharmaceutical supply chain that
 could be exploited by foreign          
adversaries and nonstate actors4  7#c7  
,review and propose solutions to        
strengthen the domestic pharmaceutical  
manufacturing workforce to support      
increased production of advanced        
pharmaceutical ingredients and finished 
drugs4  7#d7 ,assess how ,federal health
 care programs 7as defined in section   
#aabh;,b7f7 of the ,social ,security    
,act 7#db ,u4,s4,c4 #acbj;a-#g;b7f7771  
the program established under chapter   
#hi of title #e1 ,united ,states ,code1 
and provider facilities can be used to  
create a viable financial market for    

domestically made advanced              
pharmaceutical ingredients and finished 
drug products4  7#e7 ,review the        
successes and failures of ,operation    
,warp ,speed and determine if any best  
practices for public-private            
partnerships can be used to bolster     
domestic manufacturing of advanced      
pharmaceutical ingredients and finished 
drug products4  7#f7 ,estimate the      
,federal funding necessary to catalyze  
and strengthen domestic pharmaceutical  
manufacturing4  7#g7 ,identify          
facilities throughout the ,united       
,states that can be repurposed to       
produce advanced pharmaceutical         
ingredients1 especially advanced        
pharmaceutical ingredients listed on the
 essential medicines list4  7#h7        
,identify partner countries where       
advanced pharmaceutical ingredients and 
finished drug products could be         
manufactured to reduce dependence on    
,china and other countries4  7#i7       
,provide recommendations on legislative 

and regulatory actions that can be taken
 to address vulnerabilities in the      
,united ,states pharmaceutical supply   
chain and increase the number of        
manufacturers of advanced pharmaceutical
 ingredients and finished drug products 
in the ,united ,states4  7#aj7 ,identify
 and propose steps that can be taken to 
increase coordination among different   
,federal and ,state programs to increase
 manufacturing of domestic advanced     
pharmaceutical ingredients and finished 
drug products4  7c7 ,membership  7#a7   
,in general ,the ,commission shall be   
composed of at least #f but not more    
than #aa members as follows3  7,a7 ,the 
,national ,security ,advisor1 who shall 
serve as co-chair4  7,b7 ,the ,white    
,house ,domestic ,policy ,council1 who  
shall serve as co-chair4  7,c7 ,the     
,secretary of ,health and ,human        
,services4  7,d7 ,the ,secretary of     
,defense4  7,e7 ,the ,secretary of      
,state4  7,f7 ,the ,secretary of        
,commerce4  7,g7 ,not more than #e      

members as may be appointed by joint    
action of the co-chairs of the          
,commission1 from among the employees   
and officers of appropriate ,federal    
departments and agencies4  7#b7 ,terms  
,each member shall be appointed for the 
life of the ,commission4  7#c7 ,quorum  
,a majority of the ,commission shall    
constitute a quorum but a lesser number 
may hold hearings4  7d7 ,powers of      
,commission ,the ,commission may1 for   
the purpose of carrying out this ,act1  
hold hearings1 sit and act at times and 
places1 take testimony1 and receive     
evidence as the ,commission considers   
appropriate4  7e7 ,reports  7#a7 ,in    
general ,not later than #a year after   
the date of enactment of this ,act1 and 
annually thereafter until the date of   
the termination of the ,commission under
 subsection 7f71 the ,commission shall  
submit to ,congress a report detailing  
the findings1 conclusions1 and          
recommendations of the ,commission in   
fulfilling its duties under subsection  

7b74  7#b7 ,form of reports ,the reports
 described in paragraph 7#a7 shall be   
submitted in unclassified form but may  
include a classified annex4  7f7        
,termination ,the ,commission shall     
terminate on the date that is #d years  
after the date of enactment of this     
,act4  7g7 ,essential medicines list    
defined ,in this section1 the term      
essential medicines list means the list 
of the ,food and ,drug ,administration  
described in section #c7;c7 of          
,executive ,order #acidd4